Analyst: Diagnostics Sector R&D Spending Won't Match FDA Data Demands
This article was originally published in The Gray Sheet
The R&D spend to revenue ratio at emerging and established pure-play diagnostic companies is not sufficient to meet growing FDA requirements for the space, a Morgan Stanley analyst argues.
You may also be interested in...
A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.